MedImmune to work with U. of Cambridge on cancer; GlobeImmune taking second shot at IPO; CytRx opens new lab;

@FierceBiotech: ICYMI over the weekend: Chimerix started the week as a punching bag, then pulls off a TKO. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers inks a $350M deal to pair with FivePrime on immuno-oncology gold rush. Story | Follow @JohnCFierce

@DamianFierce: Amgen hits the mark in another of its 14 PhIII studies of the PCSK9-blocking evolocumab. Release | Follow @DamianFierce

@EmilyMFierce: NIH cuts, sequestration hampering cancer research. Story | Follow @EmilyMFierce

> MedImmune, the biologics research arm of AstraZeneca ($AZN), has struck up a partnership with the University of Cambridge on new cancer therapies. Story

> GlobeImmune is taking a second crack at an IPO. In this attempt, the Louisville, KY-based biotech is shooting for $35 million, roughly half of its initial target. Story

> CytRx says it's opened a new lab in Freiburg, Germany, to focus in on cancer drug research. Release

Medical Device News

@FierceMedDev: Staar got key FDA panel backing for its new ocular lens. Chances for approval now pretty high. More | Follow @FierceMedDev

@MarkHFierce: Boston Scientific gained a CE mark for new MRI-safe pacer leads. News | Follow @MarkHFierce

@MichaelGFierce: ICYMI: NeuroDerm preps for Parkinson's patch PhII trial. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Following the 5-second rule for food is like playing Russian roulette with your gut, says one molecular biologist. Article | Follow @EmilyWFierce

> Smith & Nephew clears a major U.S. regulatory hurdle for ArthroCare merger. Story

> Samsung's Galaxy S5 smartphone escapes med device label in S. Korea. More

Pharma News

@FiercePharma: Best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Story | Follow @FiercePharma

@TracyStaton: Tops at FiercePharma Wed.: CA panel shivs Gilead's Sovaldi on price, suggests focusing it on sickest hep C patients. More | Follow @TracyStaton

@EricPFierce: New twist on KV vs FDA over Makena. FDA cites compounder. News | Follow @EricPFierce

@CarlyHFierce: Going to check out South America for a few days. Talk to you Thursday, Twitterverse! | Follow @CarlyHFierce

> Bristol-Myers' Eliquis gets new FDA nod for use after ortho surgery. Article

> In latest marketing-reform move, GSK recruits in-house doctors to speak for products. More

> Shire recalls Gaucher drug but says it has plenty of supply in reserve. News

> Italian prosecutors home in on Roche, Novartis execs in eye-drug collusion probe. Story

CRO News

> Charles River snaps up Galapagos' CRO biz for $179M. News

> Clinipace dives into Asia with Choice Pharma buyout. Story

> WuXi deepens its genomics might with Illumina, Pacific Biomarkers deals. Article

> Post-merger BioClinica looks to corner the imaging market. Piece

> PPD lands a federal bioterror deal worth up to $100M. News

> Meet DPx, the result of a $2.6B CMO merger. Brief

Biotech IT News

> Illumina likely to start charging for BaseSpace storage and processing in 2014. Story

> IMS: Big Pharma must turn to tech to cut $36B from their operating costs. Article

> Public enthusiastic--but wary--about sharing personal health data. Survey

> The rise of the Silicon Valley biocomputing startup. Piece

> Drop in federal funding threatens 22 jobs at the Broad Institute. Story

> Genome data nonprofit aims to raise $25,000 through crowdfunding. Brief

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.